10-QPeriod: Q2 FY2010

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 2010

Filed August 9, 2010For Securities:GILD

Summary

Gilead Sciences, Inc. reported strong financial results for the second quarter and first half of 2010, demonstrating robust revenue growth primarily driven by its antiviral franchise, particularly Atripla and Truvada. Total revenues increased by 15% year-over-year for the quarter to $1.93 billion and 19% for the first half to $4.01 billion. Net income also saw a significant increase, reflecting improved operational efficiency and strong product demand. The company continued to invest in research and development, with key advancements in its HIV and liver disease pipelines. Gilead also announced a new $5.0 billion stock repurchase program, underscoring its commitment to returning value to shareholders and maintaining a strong financial position with substantial cash reserves.

Financial Highlights

50 data points
Beta

Revenue

$1.93B

70.1% Gross Margin

Net Income

$712.06M

36.9% Net Margin

EPS (Diluted)

$0.40

Total Assets

$10.50B

Cash & Equivalents

$1.48B

Free Cash Flow

$699.08M

Financial Statements
Beta
Revenue$1.93B
Cost of Revenue$455.52M
Gross Profit$1.35B
SG&A Expenses$248.01M
Operating Expenses$934.60M
Operating Income$992.63M
Interest Expense$17.76M
Net Income$712.06M
EPS (Basic)$0.41
EPS (Diluted)$0.40
Shares Outstanding (Basic)1.76B
Shares Outstanding (Diluted)1.80B

Key Highlights

  • 1Total revenues grew 15% to $1.93 billion in Q2 2010, driven by a 15% increase in product sales.
  • 2Antiviral product sales, led by Atripla and Truvada, increased by 13% and 16% for the three and six months ended June 30, 2010, respectively.
  • 3Net income attributable to Gilead common stockholders increased to $712.1 million for the quarter, up from $571.4 million in Q2 2009.
  • 4The company initiated significant Phase 3 clinical studies for its next-generation HIV treatment regimen.
  • 5Gilead announced a new $5.0 billion, three-year stock repurchase program, demonstrating confidence in future performance and commitment to shareholder returns.
  • 6Cash, cash equivalents, and marketable securities increased to $4.22 billion as of June 30, 2010, providing strong liquidity.
  • 7The company is actively managing potential impacts of the U.S. healthcare reform legislation, estimating a ~$200 million reduction in U.S. net product sales for 2010.

Frequently Asked Questions

Gilead's revenue growth in the second quarter of 2010 was primarily driven by its antiviral franchise, with significant contributions from Atripla and Truvada. Product sales increased by 15% year-over-year, with Atripla sales alone growing 26% due to strong volume growth in the United States and Europe.

Gilead maintained a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $4.22 billion as of June 30, 2010, an increase from December 31, 2009. The company also has access to a $1.25 billion revolving credit facility, of which $745.5 million was available at quarter-end. Gilead also announced a new $5.0 billion stock repurchase program.

Gilead is advancing its pipeline with key developments in HIV, including initiating Phase 3 studies for a complete single-tablet fixed-dose regimen containing elvitegravir. The company is also developing a new once-daily fixed-dose combination for HIV with Tibotec and has advanced its liver disease and respiratory programs, including hepatitis C treatments and Cayston for cystic fibrosis.

Gilead estimates the U.S. healthcare reform legislation will reduce its 2010 U.S. net product sales by approximately $200 million, primarily due to increased rebates and discounts. The company is actively monitoring and managing the evolving regulatory landscape.